Benjamin Switzer

Benjamin Switzer

Auto-generated profile, based on publicly available information

Benjamin Switzer

Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in JCO Oncology Practice
Verified
Journal Article
Closed access
BSBenjamin Switzer
Benjamin Switzer
IPIgor Puzanov
Igor Puzanov
JSJoseph Skitzki
Joseph Skitzki
LHLamya Hamad
Lamya Hamad
MEMarc S Ernstoff
Marc S Ernstoff
Cutaneous melanoma remains the most lethal of the primary cutaneous neoplasms, and although the incidence of primary melanoma continues to rise, the mortality from metastatic disease remains unchanged, in part through advances in treatment. Major developments in immunomodulatory and targeted therapies have provided robust improvements in response and survival trends that have transformed the clinical management of patients with metastatic melanoma. Additional advances in immunologic and cancer cell biology have contributed to further optimization in (1) risk stratification, (2) prognostication, (3) treatment, (4) toxicity management, and (5) surveillance approaches for patients with an advanced melanoma diagnosis. In this review, we provide a comprehensive overview of the historical and future advances regarding the translational and clinical implications of advanced melanoma and share multidisciplinary recommendations to aid clinicians in the navigation of current treatment approaches for a variety of patient cohorts.

23 June 2021 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
IPIgor Puzanov
Igor Puzanov
PSPoornima Subramanian
Poornima Subramanian
YYYan V Yatsynovich
Yan V Yatsynovich
DJDavid M Jacobs
David M Jacobs
MCMaya R Chilbert
Maya R Chilbert
JSJerome J Schentag
Jerome J Schentag
Background Immune checkpoint inhibitors (ICI) have emerged as a front-line therapy for a variety of solid tumors. With the widespread use of these agents, immune-associated toxicities are increasingly being recognized, including fatal myocarditis. There are limited data on the outcomes and prognostic utility of biomarkers associated with ICI-associated myocarditis. Our objective was to examine the associations between clinical biomarkers of cardiomyocyte damage and mortality in patients with cancer treated with ICIs. Methods We retrospectively studied 23 patients who developed symptomatic and asymptomatic troponin elevations while receiving ICI therapy at a National Cancer Institute-designated comprehensive cancer center. We obtained serial ECGs, troponin I, and creatine kinase-MD (CK-MB), in addition to other conventional clinical biomarkers, and compared covariates between survivors and non-survivors. Results Among patients with myocarditis, higher troponin I (p=0.037) and CK-MB (p=0.034) levels on presentation correlated with progression to severe myocarditis. Higher troponin I (p=0.016), CK (p=0.013), and CK-MB (p=0.034) levels were associated with increased mortality, while the presence of advanced atrioventricular block on presentation (p=0.088) trended toward increased mortality. Weekly troponin monitoring lead to earlier hospitalization for potential myocarditis (p=0.022) and was associated with decreased time to steroid initiation (p=0.053) and improved outcomes. Conclusions Routine troponin surveillance may be helpful in predicting mortality in ICI-treated patients with cancer in the early phase of ICI therapy initiation. Early detection of troponin elevation is associated with earlier intervention and improved outcomes in ICI-associated myocarditis. The recommended assessment and diagnostic studies guiding treatment decisions are presented.

30 May 2024 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
HBHannah R Burnette
Hannah R Burnette
APAliyah Pabani
Aliyah Pabani
MIMitchell S von Itzstein
Mitchell S von Itzstein
BSBenjamin Switzer
Benjamin Switzer
RFRun Fan
Run Fan
DJDouglas B Johnson
Douglas B Johnson
Background Artificial intelligence (AI) chatbots have become a major source of general and medical information, though their accuracy and completeness are still being assessed. Their utility to answer questions surrounding immune-related adverse events (irAEs), common and potentially dangerous toxicities from cancer immunotherapy, are not well defined. Methods We developed 50 distinct questions with answers in available guidelines surrounding 10 irAE categories and queried two AI chatbots (ChatGPT and Bard), along with an additional 20 patient-specific scenarios. Experts in irAE management scored answers for accuracy and completion using a Likert scale ranging from 1 (least accurate/complete) to 4 (most accurate/complete). Answers across categories and across engines were compared. Results Overall, both engines scored highly for accuracy (mean scores for ChatGPT and Bard were 3.87 vs 3.5, p<0.01) and completeness (3.83 vs 3.46, p<0.01). Scores of 1–2 (completely or mostly inaccurate or incomplete) were particularly rare for ChatGPT (6/800 answer-ratings, 0.75%). Of the 50 questions, all eight physician raters gave ChatGPT a rating of 4 (fully accurate or complete) for 22 questions (for accuracy) and 16 questions (for completeness). In the 20 patient scenarios, the average accuracy score was 3.725 (median 4) and the average completeness was 3.61 (median 4). Conclusions AI chatbots provided largely accurate and complete information regarding irAEs, and wildly inaccurate information (“hallucinations”) was uncommon. However, until accuracy and completeness increases further, appropriate guidelines remain the gold standard to follow

1 October 2020 in The American Journal of the Medical Sciences
Verified
Journal Article
Closed access
ABAndrei Brateanu
Andrei Brateanu
BSBenjamin Switzer
Benjamin Switzer
SSSusan C. Scott
Susan C. Scott
JRJennifer Ramsey
Jennifer Ramsey
JTJames Thomascik
James Thomascik
CCColleen Y. Colbert
Colleen Y. Colbert

28 January 2019 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
GKGirish Kunapareddy
Girish Kunapareddy
BSBenjamin Switzer
Benjamin Switzer
PJPrantesh Jain
Prantesh Jain
MCMadison Conces
Madison Conces
YCYu‐Wei Chen
Yu‐Wei Chen
AKAlok A. Khorana
Alok A. Khorana
Background Venous thromboembolism (VTE) is a major cause of morbidity, mortality, and hospitalization in cancer patients. Objectives To evaluate the feasibility of an electronic alert to identify and screen at‐risk individuals and gather rates of early detection of deep vein thrombosis (DVT). Patients/Methods An alert was built into the electronic medical record based on a validated risk tool (Khorana Score [KS]) and outcomes evaluated in an initial silent phase. The alert functioned in real time to warn physicians of high‐risk patients (KS ≥ 3) and suggested lower extremity screening ultrasonography in a subsequent active phase. Results Of 194 consecutive patients identified as high risk in the silent phase, 14 (7.2%) developed subsequent DVT or pulmonary embolism (PE) over 90‐day follow‐up, with a median of 27 days. Mean 90‐day emergency room (ER) visits, all‐cause admissions, and length of stay (days) for patients with DVT were 1.2, 1.6, and 9.1 compared to 0.89, 0.93, and 5.1 for all patients, respectively. In the active phase, 197 consecutive alerts met inclusion criteria, and 40 patients (20.3%) received a screening ultrasound. Five (12.5%) had a DVT and were started on therapeutic anticoagulation. Of patients with alerts who had screening deferred, 13 (8.3%) were later diagnosed with DVT (median 50.5 days) and 7 (4.5%) with PE. Conclusion An automated alert may have value in early detection of DVT in high‐risk cancer patients leading to earlier intervention, and could potentially prevent VTE‐related morbidity.

16 July 2021 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
BSBenjamin Switzer
Benjamin Switzer
JHJohn Haanen
John Haanen
PLPaul C Lorigan
Paul C Lorigan
IPIgor Puzanov
Igor Puzanov
STSamra Turajlic
Samra Turajlic
The clinical and immunologic implications of the SARS-CoV-2 pandemic for patients with cancer receiving systemic anticancer therapy have introduced a multitude of clinical challenges and academic controversies. This review summarizes the current evidence, discussion points, and recommendations regarding the use of immune checkpoint inhibitors (ICIs) in patients with cancer during the SARS-CoV-2 pandemic, with a focus on patients with melanoma and renal cell carcinoma (RCC). More specifically, we summarize the theoretical concepts and available objective data regarding the relationships between ICIs and the antiviral immune response, along with recommended clinical approaches to the management of melanoma and RCC patient cohorts receiving ICIs throughout the course of the COVID-19 pandemic. Additional insights regarding the use of ICIs in the setting of current and upcoming COVID-19 vaccines and broader implications toward future pandemics are also discussed.